Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, Cambridgeshire, UK.
Department of Medicine, University of Cambridge, Cambridge, Cambridgeshire, UK.
Science. 2021 Feb 19;371(6531):839-846. doi: 10.1126/science.aaz6964.
Organoid technology holds great promise for regenerative medicine but has not yet been applied to humans. We address this challenge using cholangiocyte organoids in the context of cholangiopathies, which represent a key reason for liver transplantation. Using single-cell RNA sequencing, we show that primary human cholangiocytes display transcriptional diversity that is lost in organoid culture. However, cholangiocyte organoids remain plastic and resume their in vivo signatures when transplanted back in the biliary tree. We then utilize a model of cell engraftment in human livers undergoing ex vivo normothermic perfusion to demonstrate that this property allows extrahepatic organoids to repair human intrahepatic ducts after transplantation. Our results provide proof of principle that cholangiocyte organoids can be used to repair human biliary epithelium.
类器官技术在再生医学方面具有广阔的前景,但尚未应用于人类。我们在胆管疾病的背景下使用胆管细胞类器官来解决这一挑战,胆管疾病是肝移植的主要原因之一。通过单细胞 RNA 测序,我们发现原代人胆管细胞显示出转录多样性,而这种多样性在类器官培养中丢失了。然而,胆管细胞类器官仍然具有可塑性,当它们被重新移植到胆管树中时,会恢复其体内特征。然后,我们利用在经历离体常温灌流的人类肝脏中进行细胞移植的模型,证明了这一特性使肝外类器官能够在移植后修复人类肝内胆管。我们的研究结果为胆管细胞类器官可用于修复人类胆道上皮提供了原理证明。